Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abiraterone Acetate

FDA-approved product (tablet, oral), marketed as Abiraterone Acetate, Yonsa, Zytiga.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Abiraterone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other hormone antagonists and related agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abiraterone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abiraterone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

    NCT02703623 · start 2016-05-18

    Registered record
    Registry ID
    NCT02703623
    Conditions
    Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7
    Interventions
    Abiraterone Acetate; Apalutamide; Cabazitaxel; Carboplatin; Ipilimumab; Laboratory Biomarker Analysis; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-05-18
    Completion
    2028-03-31
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; PSA Progression +1 more
    InterventionAbiraterone Acetate; Apalutamide; Cabazitaxel; Carboplatin +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Optimizing Abiraterone Therapy

    NCT02426333 · start 2016-01

    Registered record
    Registry ID
    NCT02426333
    Conditions
    Metastatic Castration Resistant Prostate Cancer
    Interventions
    Abiraterone Acetate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-01
    Completion
    2019-08-01
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration Resistant Prostate Cancer
    InterventionAbiraterone Acetate
    PhaseNot recorded
    Registry statusCompleted

  • Abiraterone-Rechallenge Study for CRPC Patients

    NCT02656615 · start 2016-01

    Registered record
    Registry ID
    NCT02656615
    Conditions
    Prostate Cancer
    Interventions
    abiraterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-01
    Completion
    2017-02
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionabiraterone acetate
    PhasePhase 2
    Registry statusTerminated

  • Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers

    NCT02867852 · start 2015-03

    Registered record
    Registry ID
    NCT02867852
    Conditions
    Salivary Glands Tumors
    Interventions
    Abiraterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-03
    Completion
    2020-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSalivary Glands Tumors
    InterventionAbiraterone acetate
    PhasePhase 2
    Registry statusCompleted

  • A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

    NCT02159690 · start 2014-09

    Registered record
    Registry ID
    NCT02159690
    Conditions
    Prostate Cancer; Localized Prostate Cancer
    Interventions
    Enzalutamide; Abiraterone acetate; Prednisone; Dutasteride; Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2014-09
    Completion
    2015-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Localized Prostate Cancer
    InterventionEnzalutamide; Abiraterone acetate; Prednisone; Dutasteride +1 more
    PhasePhase 2
    Registry statusWithdrawn

  • A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

    NCT02123758 · start 2014-07-09

    Registered record
    Registry ID
    NCT02123758
    Conditions
    Prostatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer
    Interventions
    Abiraterone Acetate; Prednisone; JNJ-56021927
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2014-07-09
    Completion
    2027-12-31
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer
    InterventionAbiraterone Acetate; Prednisone; JNJ-56021927
    PhasePhase 1
    Registry statusActive not recruiting

  • ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

    NCT02106507 · start 2014-04

    Registered record
    Registry ID
    NCT02106507
    Conditions
    Prostate Cancer
    Interventions
    apalutamide; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2021-06-28
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionapalutamide; Everolimus
    PhasePhase 1
    Registry statusCompleted

  • Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

    NCT01692483 · start 2013-07

    Registered record
    Registry ID
    NCT01692483
    Conditions
    Prostate Neoplasms
    Interventions
    Abiraterone acetate; Prednisone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2013-07
    Completion
    2016-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Neoplasms
    InterventionAbiraterone acetate; Prednisone
    PhaseNot recorded
    Registry statusWithdrawn

  • Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate

    NCT01858441 · start 2013-04

    Registered record
    Registry ID
    NCT01858441
    Conditions
    Pharmacogenetic Study
    Interventions
    Abiraterone Acetate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-04
    Completion
    2020-12-03
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacogenetic Study
    InterventionAbiraterone Acetate
    PhaseNot applicable
    Registry statusCompleted

  • Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery

    NCT01780220 · start 2012-12

    Registered record
    Registry ID
    NCT01780220
    Conditions
    Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy
    Interventions
    Abiraterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-12
    Completion
    2022-01-07
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy
    InterventionAbiraterone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

    NCT01688492 · start 2012-09

    Registered record
    Registry ID
    NCT01688492
    Conditions
    Prostate Cancer
    Interventions
    Ipilimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2012-09
    Completion
    2026-09
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionIpilimumab
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants

    NCT01678573 · start 2012-07

    Registered record
    Registry ID
    NCT01678573
    Conditions
    Healthy
    Interventions
    Treatment A: abiraterone acetate; Treatment B: abiraterone acetate; Treatment C: abiraterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07
    Completion
    2012-09
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTreatment A: abiraterone acetate; Treatment B: abiraterone acetate; Treatment C: abiraterone acetate
    PhasePhase 1
    Registry statusCompleted

  • A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone

    NCT01857908 · start 2012-06

    Registered record
    Registry ID
    NCT01857908
    Conditions
    Prostate Cancer (Adenocarcinoma)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-06
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer (Adenocarcinoma)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet

    NCT01640093 · start 2012-05

    Registered record
    Registry ID
    NCT01640093
    Conditions
    Healthy Participants
    Interventions
    Abiraterone acetate, 250 mg (uncoated, current commercial tablet); Abiraterone acetate, 500 mg (coated, reformulated tablet); Abiraterone acetate, 250 mg (coated, reformulated tablet); Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-05
    Completion
    2012-07
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAbiraterone acetate, 250 mg (uncoated, current commercial tablet); Abiraterone acetate, 500 mg (coated, reformulated tablet); Abiraterone acetate, 250 mg (coated, reformulated tablet); Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
    PhasePhase 1
    Registry statusCompleted

  • A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

    NCT01424930 · start 2011-10

    Registered record
    Registry ID
    NCT01424930
    Conditions
    Prostate Neoplasms; Prostate Cancer
    Interventions
    Abiraterone; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-10
    Completion
    2013-05
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Neoplasms; Prostate Cancer
    InterventionAbiraterone; Prednisone
    PhasePhase 2
    Registry statusCompleted